Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
|Articles|July 12, 2015
Drug Spending Spike Highlights Specialty Pharmacy Week in Review
Author(s)Davy James, Managing Editor
Top stories of the week on Specialty Pharmacy Times from July 6 to July 10.
Advertisement
[<a href="//storify.com/pharmacytimes/drug-spending-spike-highlights-specialty-pharmacy-" target="_blank">View the story "Drug Spending Spike Highlights Specialty Pharmacy Week in Review" on Storify</a>]
Advertisement
Related to this article
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.
Pharmacists can support effective cancer pain treatment by starting constipation prevention with opioid therapy and reassessing bowel function before symptoms become a barrier to care.
Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cystatin C and the Future of Kidney Function Assessment
2
Walgreens Adds Pharmacist Outreach, Coverage Help for GLP-1s
3
GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD
4
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
5